Featured Publications
Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
Yap D, Leone A, Wong N, Zhao J, Tey J, Sundar R, Pietrantonio F. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma. JAMA Oncology 2023, 9: 215-224. PMID: 36480211, PMCID: PMC9857522, DOI: 10.1001/jamaoncol.2022.5816.Peer-Reviewed Original ResearchConceptsAdvanced esophageal squamous cell carcinomaImmune checkpoint inhibitorsEsophageal squamous cell carcinomaSquamous cell carcinomaPD-L1 expressionKaplan-Meier curvesLow PD-L1 expressionFirst-line trialsProgression-free survivalDuration of responsePD-L1Overall survivalCell carcinomaRandomized clinical trialsPooled analysisClinical trialsCheckpoint inhibitorsTumor proportionEffect of immune checkpoint inhibitorsLow programmed death ligand 1Benefit of immune checkpoint inhibitorsHazard ratioSurvival dataFirst-line settingICI-based regimens
2024
Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups
Leone A, Mai A, Fong K, Yap D, Kato K, Smyth E, Moehler M, Seong J, Sundar R, Zhao J, Pietrantonio F. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups. ESMO Open 2024, 9: 103962. PMID: 39426081, PMCID: PMC11533044, DOI: 10.1016/j.esmoop.2024.103962.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCombined positive scoreBenefit of immune checkpoint inhibitorsCheckpoint inhibitorsOS benefitOverall survivalAnti-programmed cell death protein 1Kaplan-Meier (KM) plotsEfficacy of immune checkpoint inhibitorsFirst-line immune checkpoint inhibitorsPD-L1 combined positive scoreProgrammed death ligand 1 subgroupsCell death protein 1Programmed death-ligand 1Patient-level meta-analysesPatient-level meta-analysisDeath-ligand 1Advanced gastroesophageal adenocarcinomaRandomized clinical trialsCheckMate-649KEYNOTE-062Gastroesophageal adenocarcinomaTherapeutic optionsClinical trialsKM plots